Navigation Links
Truly sick or simply scared?
Date:8/19/2007

BOSTON Scientists at Pacific Northwest National Laboratory have discovered a way to increase the sensitivity of test strips that will enable creation of a portable biosensor that can address a major concern associated with incidents involving chemical or nerve agents the need to quickly distinguish between individuals who have been exposed and the worried well.

The sensor components resemble a pregnancy test strip and a small glucose testing meter. Its development will be discussed by principal investigator Yuehe Lin at the national meeting of the American Chemical Society.

Every disease has biomarkers, a change in the proteins that announces something is wrong. Lin and his team are creating a nanoparticle label that can increase the ability of a sensor to detect and interpret the message of biomarkers.

Current test strip based-immunoassay technology has very good selectivity, but it can only give a positive or negative response, Lin said.

The researchers are working with an electrochemical immunoassay approach. This involves using the antibody of a specific disease a protein produced in response to an invading bacterium or other foreign substance to attract the biomarker. Lin found that labeling a second antibody with a nanoparticle amplifies the biomarkers signal. Greater amplification means more precise readings.

Researchers at PNNL are developing a portable biomonitor to rapidly evaluate tiny samples of blood or saliva for exposure to nerve agents.

Lin achieves this by removing the iron from a nanoparticle-sized ball of the protein ferrin, creating an empty cage called apoferritin, which he then loads with another metal, such as cadmium. The cadmium-fi lled cage is attached to one end of the reporting antibody, and the immuno-reaction product becomes electroactive.

The electrochemical signal is amplified several hundreds to thousand times because of the metal ions, Lin said. This level of sensitivity will allow detectors to be very precise in identifying the concentration of biomarkers in biological samples.


'/>"/>

Contact: Geoff Harvey
geoffrey.harvey@pnl.gov
509-372-6083
DOE/Pacific Northwest National Laboratory
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: